Compare MobilEye Global Inc (MBLY) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Nuwellis Inc — how do they compare? MobilEye Global Inc trades at $7.07 (market cap $6.08B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: MobilEye Global Inc is far larger — about 2763.6× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 4,250,290). Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Nuwellis Inc for 26 Days on average.
| MBLY | NUWE | |
|---|---|---|
Market Cap | $6.08B | $2.20M |
Volume | 4,250,290 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $146.65 |
52-Week Low | $6.56 | $0.68 |
Typical Hold Time | 15 Days | 26 Days |
Enterprise Value | $4.64B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.15, down 4.28% amid bearish technical signals, though RSI levels suggest potential oversold conditions. The company shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep losses (-$4.1B net income). Analyst consensus remains positive with 57.7% buy ratings and $10.83 price target, while recent news highlights ADAS business momentum and autonomous vehicle expansion initiatives.
MBLY presents a high-risk opportunity with significant upside potential if execution improves, but current profitability challenges and bearish technicals warrant caution. The stock trades below book value (P/B 0.74) with institutional confidence shown through recent insider buying, though competitive pressures in autonomous driving and ongoing losses represent substantial investor risks.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
